The whole process management principles of chimeric antigen receptor T-cell therapy for lymphoma at Peking University Cancer Hospital
10.3760/cma.j.cn115356-20210923-00227
- VernacularTitle:北京大学肿瘤医院嵌合抗原受体T细胞治疗淋巴瘤全流程管理原则
- Author:
Zhitao YING
1
;
Ningjing LIN
;
Meng WU
;
Bo MA
;
Hongzhi WANG
;
Chun ZENG
;
Shuling MA
;
Xinling ZHAO
;
Yan XIE
;
Weiping LIU
;
Yuqin SONG
;
Jun ZHU
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Lymphoma;
Large B-cell lymphoma;
Chimeric antigen receptor T cell;
Antigens, CD19
- From:
Journal of Leukemia & Lymphoma
2021;30(11):674-684
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T (CAR-T) cell has achieved excellent efficacy in hematological tumors, especially for lymphoma. Many products have been approved to market all over the world, and 2 products targeting CD19 have been approved to treat relapsed and refractory large B-cell lymphoma in China. The current experiences of using CAR-T cells come from previous clinical studies. How to use CAR-T cells in a standardized and rationalized way is still a challenge faced by our clinicians. Based on the CAR-T cell treatment experiences from Peking University Cancer Hospital and the latest research progresses in CAR-T in China and abroad, this article will elaborate on patient screening, peripheral blood mononuclear cell collection, bridging treatment, lymphocyte depletion chemotherapy, CAR-T cell infusion, the monitoring and treatment of adverse events after infusion, and long-term follow-up after infusion, in order to guide clinicians to better use CAR-T cell and to bring maximum benefits to patients.
